Literature DB >> 12049975

Examination of rofecoxib solution decomposition under alkaline and photolytic stress conditions.

Bing Mao1, Ahmed Abrahim, Zhihong Ge, Dean K Ellison, Robert Hartman, Sunil V Prabhu, Robert A Reamer, Jean Wyvratt.   

Abstract

Rofecoxib is a highly active and selective cyclo-oxygenase II inhibitor. A stability-indicating method for the assay of rofecoxib has been developed using reverse-phase high-performance liquid chromatography (HPLC). Stress testing of rofecoxib was conducted during the method development and validation. HPLC analysis of rofecoxib solutions stressed under alkaline and photolytic conditions revealed the presence of several degradates. Two main degradates were determined to be the cyclization product formed by photo-cyclization and the dicarboxylate formed by ring opening in the presence of base and oxygen. The identities of these degradates were confirmed by comparison of UV spectra and HPLC retention time with the independently synthesized products. The mechanistic pathways for the formation of these degradates are discussed. Further improvement of the HPLC method's ruggedness has been made based on these studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12049975     DOI: 10.1016/s0731-7085(01)00716-6

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Mechanism of the solution oxidation of rofecoxib under alkaline conditions.

Authors:  Paul A Harmon; Stephen Biffar; Steven M Pitzenberger; Robert A Reed
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

2.  Structural Examination of 6-Methylsulphonylphenanthro- [9,10-C]-furan-1(3H)-one-A Rofecoxib Degradation Product.

Authors:  Pamela M Dean
Journal:  Pharmaceuticals (Basel)       Date:  2010-02-01

3.  Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.

Authors:  Antonio Buzharevski; Svetlana Paskaš; Menyhárt-Botond Sárosi; Markus Laube; Peter Lönnecke; Wilma Neumann; Blagoje Murganić; Sanja Mijatović; Danijelа Maksimović-Ivanić; Jens Pietzsch; Evamarie Hey-Hawkins
Journal:  Sci Rep       Date:  2020-03-16       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.